CoChat

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial

Open access
Landgren, Ola, Hultcrantz, Malin, Diamond, Benjamin, Lesokhin, Alexander M., Mailankody, Sham, Hassoun, Hani, Tan, Carlyn, Shah, Urvi A, Lu, Sydney X., Salcedo, Meghan, Werner, Kelly, Rispoli, Jenna, Caple, Julia, Sams, Allison, Verducci, Dennis, Jones, Katie, Concepcion, Isabel, Ciardello, Amanda, Chansakul, Aisara, Schlossman, Julia, Tavitian, Elizabet, Shekarkhand, Tala, Harrison, Angela, Piacentini, Casey, Rustad, Even H., Yellapantula, Venkata, Maclaughlan, Kylee, Maura, Francesco, Landau, Heather J., Scordo, Michael, Chung, David J., Shah, Gunjan, Lahoud, Oscar B., Thoren, Katie, Murata, Kazunori, Ramanathan, Lakshmi, Arcila, Maria E., Ho, Caleb, Roshal, Mikhail, Dogan, Ahmet, Derkach, Andriy, Giralt, Sergio A., Korde, Neha · 2021 · JAMA Oncology
Cited by 119

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

IMPORTANCE: Recently, the benefit of adding daratumumab to the proteasome inhibitor-based, 3-drug combination of bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma who underwent high-dose melphalan chemotherapy and autologous hemopoietic cell transplant was assessed. Here, we examine the addition of daratumumab to the second-generation proteasome inhibitor-based, 3-drug combination of carfilzomib, lenalidomide, and dexamethasone. OBJECTIVE: To assess the safety and effectiveness of carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy for patients with newly diagnosed multiple myeloma, in the absence of high-dose melphalan chemotherapy and autologous hemopoietic cell transplant. DESIGN, SETTING, AND PARTICIPANTS: Clinical and correlative pilot study at the Memorial Sloan Kettering Cancer Center in New York, New York. Patients with newly diagnosed multiple myeloma were enrolled between October 1, 2018, and November 15, 2019. The median follow-up from start of treatment was 20.3 months (95% CI, 19.2-21.9 months). INTERVENTIONS: Eight 28-day cycles with intravenous carfilzomib, 20/56 mg/m2 (days 1, 8, and 15); oral lenalidomide, 25 mg, (days 1-21); dexamethasone, 40 mg weekly, orally or intravenously (cycles 1-4), and 20 mg after cycle 4; and intravenous daratumumab, 16 mg/kg (days 1, 8, 15, and 22 [cycles 1-2]; days 1 and 15 [cycles 3-6]; and day 1 [cycles 7 and 8]). MAIN OUTCOMES AND MEASURES: The primary end point was the minimal residual disease (MRD) rate, in the absence of high-dose melphalan chemotherapy and autologous hemopoietic cell transplant. Secondary end points included determining safety and tolerability, evaluating rates of clinical response per the International Myeloma Working Group, and estimating progression-free survival (PFS) and overall survival (OS) rates. RESULTS: Forty-one evaluable patients were enrolled (median age, 59 years; range, 30-70 years); 25 (61%) were female, and 20 (49%) had high-risk multiple myeloma. The primary end point (MRD negativity in the bone marrow; 10-5 sensitivity) was achieved in 29 of 41 patients (71%; 95% CI, 54%-83%), and therefore the trial was deemed successful. Median time to MRD negativity was 6 cycles (range, 1-8 cycles). Secondary end points of the overall response rate and the very good partial response or complete response rate were 100% (41 of 41 patients) and 95% (39 of 41 patients), respectively. At 11 months of the median follow-up, the 1-year PFS rate and the OS rate were 98% (95% CI, 93%-100%) and 100%, respectively. Most common (≥2 patients) grade 3 or 4 adverse events were neutropenia (12 patients [27%]), rash (4 patients [9%]), lung infection (3 patients [7%]), and increased alanine aminotransferase level (2 patients [4%]). There were no deaths. CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy was associated with high rates of MRD negativity in patients with newly diagnosed multiple myeloma and high rates of PFS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2021.0611

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 119

Metadata

Authors
Landgren, O., Hultcrantz, M., Diamond, B., Lesokhin, A. M., Mailankody, S., Hassoun, H., Tan, C., Shah, U. A., Lu, S. X., Salcedo, M., Werner, K., Rispoli, J., Caple, J., Sams, A., Verducci, D., Jones, K., Concepcion, I., Ciardello, A., Chansakul, A., Schlossman, J., Tavitian, E., Shekarkhand, T., Harrison, A., Piacentini, C., Rustad, E. H., Yellapantula, V., Maclaughlan, K., Maura, F., Landau, H. J., Scordo, M., Chung, D. J., Shah, G., Lahoud, O. B., Thoren, K., Murata, K., Ramanathan, L., Arcila, M. E., Ho, C., Roshal, M., Dogan, A., Derkach, A., Giralt, S. A., & Korde, N.
Venue
JAMA Oncology
Published
2021-06-01
Volume
7
Issue
6
Pages
862
ISSN
2374-2437 (ISSN-L)
OpenAlex
W3153907740
Cited by
119
References
10
FWCI
11.94
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaoncol.2021.0611
The paper
Landgren, O., Hultcrantz, M., Diamond, B., Lesokhin, A. M., Mailankody, S., Hassoun, H., Tan, C., Shah, U. A., Lu, S. X., Salcedo, M., Werner, K., Rispoli, J., Caple, J., Sams, A., Verducci, D., Jones, K., Concepcion, I., Ciardello, A., Chansakul, A., . . . Korde, N. (2021). Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2021.0611

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.